Domača stranNVS • NYSE
add
Novartis
103,81 $
Po zaprtju:(0,00 %)0,00
103,81 $
Konec trgovanja: 26. nov., 17:17:27 GMT -5 · USD · NYSE · Izjava
Prejšnji trg. dan.
103,54 $
Dnevni razpon
103,25 $ - 104,09 $
Letni razpon
92,35 $ - 120,92 $
Tržna kapitalizacija
230,15 mrd. USD
Povprečni obseg
1,25 mio.
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(USD) | sep. 2024info | Sprememba L/L |
---|---|---|
Prihodek | 13,17 mrd. | 8,93 % |
Stroški poslovanja | 5,52 mrd. | −24,45 % |
Čisti dohodek | 3,19 mrd. | 81,09 % |
Čista dobičkovnost prihodkov | 24,21 | 66,28 % |
Earnings per share | 2,06 | 18,39 % |
EBITDA | 5,50 mrd. | 88,62 % |
Efektivna davčna stopnja | 5,91 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(USD) | sep. 2024info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 13,85 mrd. | 8,08 % |
Skupna sredstva | 103,52 mrd. | −8,14 % |
Skupne obveznosti | 60,08 mrd. | −19,30 % |
Celoten lastniški kapital | 43,44 mrd. | — |
Shares outstanding | 2,00 mrd. | — |
Razmerje P/B | 4,78 | — |
Donosnost sredstev | 10,97 % | — |
Donosnost kapitala | 15,05 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(USD) | sep. 2024info | Sprememba L/L |
---|---|---|
Čisti dohodek | 3,19 mrd. | 81,09 % |
Denar iz dejavnosti | 6,29 mrd. | 16,88 % |
Denar iz naložb | −374,00 mio. | 83,09 % |
Denar iz financiranja | −382,00 mio. | 54,09 % |
Neto sprememba denarnih sredstev | 5,71 mrd. | 275,39 % |
Prost denarni tok | 4,55 mrd. | −63,57 % |
Vizitka
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes”.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Generalni direktor
Datum ustanovitve
29. feb. 1996
Sedež organizacije
Spletno mesto
Zaposleni
76.057